2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Mann A, Nair A, Nassif M, Poulsen S, Reant P, Schulze P, Wang A, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Sohn R, Wohltman A, Fifer M, Investigators M. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Failure 2025, 13: 346-357. PMID: 39909646, DOI: 10.1016/j.jchf.2024.11.011.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyStandard-of-careCardiac myosin inhibitorStandard-of-care medicationsBaseline characteristicsSymptomatic obstructive hypertrophic cardiomyopathyNondihydropyridine calcium channel blockersBaseline characteristics of patientsStandard-of-care drugsSecond-line therapyFirst-line therapyCalcium channel blockersCharacteristics of patientsImprove exercise capacityMyosin inhibitorFirst-lineBeta-blockersHypertrophic cardiomyopathyExercise capacityAlleviate symptomsPatientsAficamtenMedicationTherapyStudy design
2024
Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
Y K, Lee P, Chowdhury I, Schwartz R, Kang Y, Mangalesh S, Babapour G, Akman Z, Chang Y, Song J, Lessa Y, Damluji A, Nanna M, Nanna M. Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis. European Heart Journal 2024, 45: ehae666.1640. DOI: 10.1093/eurheartj/ehae666.1640.Peer-Reviewed Original ResearchRandomized Controlled TrialsReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitReduced EFMeta-RegressionEF patientsPreserved EFBB usersReperfusion eraMeta-analysisSubgroup analysisSystematic reviewPost-MIPost-MI careEffect of beta-blockersIncreased all-cause mortalityHistory of HFEvent-free periodAll-Cause MortalityTemporal trendsStudy inclusion periodModern randomized controlled trialsBeta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis
Chi K, Lee P, Chowdhury I, Akman Z, Mangalesh S, Song J, Satish V, Babapour G, Kang Y, Schwartz R, Chang Y, Borkowski P, Nanna M, Damluji A, Nanna M. Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis. European Journal Of Preventive Cardiology 2024, 32: 633-646. PMID: 39298680, PMCID: PMC11922798, DOI: 10.1093/eurjpc/zwae298.Peer-Reviewed Original ResearchReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitBB useReduced EFCV mortalityPost-MIRandom-effects meta-analysisMeta-analysisHistory of HFAll-Cause MortalityTemporal trendsPrespecified subgroup analysesEvent-free periodCardiovascular (CVIncreased CV mortalityStudy inclusion periodPost-myocardial infarctionContemporary dataAssociated with detrimental effectsNon-significant trendSecondary preventionBB usersInvestigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis
Mutonga M, Shewarega A, Gross M, Kahl V, Madoff D. Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis. Clinical Imaging 2024, 115: 110283. PMID: 39278042, DOI: 10.1016/j.clinimag.2024.110283.Peer-Reviewed Original ResearchBeta-blockersTumor responseImaging timepointsTumor sizeEtiology of liver diseaseAssociated with high mortalityTransplant free survivalTransplant-free survivalTreatment of hepatocellular carcinomaFavorable clinical outcomesChild-Pugh scoreFirst-line treatmentBeta-blocker groupPredictors of survivalCox regression analysisTreatment of HCCStudent's t-testFree survivalTransarterial chemoembolizationChi-square testPost-TACETACE treatmentPugh scoreSurvival predictorsAdjunctive usePredicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices
Giuffrè M, Dupont J, Visintin A, Masutti F, Monica F, You K, Shung D, Crocè L. Predicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices. Hepatology International 2024, 19: 460-471. PMID: 38664292, PMCID: PMC12003444, DOI: 10.1007/s12072-024-10649-7.Peer-Reviewed Original ResearchHigh-risk varicesHepatic venous pressure gradientLiver stiffnessLiver cirrhosisSpleen stiffnessVariceal gradeHeart rateCohort of cirrhotic patientsNon-selective beta-blockersPercentual decreaseAssessed therapeutic responseMultivariate modelVenous pressure gradientCut-off valueOptimal cut-offAssociated with better predictionNSBB treatmentPrimary prophylaxisHemorrhagic episodesCirrhotic patientsTherapeutic responseBeta-blockersNSBBTreatment initiationProspective studyASSOCIATION BETWEEN BETA-BLOCKER AND SURVIVAL OUTCOMES IN STABLE CORONARY ARTERY DISEASE PATIENTS WITHOUT PRIOR MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Chi K, Huang C, Nanna M, Nanna M, Romero L, Chang Y, Satish V, Naser A, Huang S, Song J. ASSOCIATION BETWEEN BETA-BLOCKER AND SURVIVAL OUTCOMES IN STABLE CORONARY ARTERY DISEASE PATIENTS WITHOUT PRIOR MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Journal Of The American College Of Cardiology 2024, 83: 1243. DOI: 10.1016/s0735-1097(24)03233-9.Peer-Reviewed Original ResearchEarly Beta-Blocker Utilization in Critically Ill Patients With Moderate-Severe Traumatic Brain Injury: A Retrospective Cohort Study
Kelly-Hedrick M, Liu S, Komisarow J, Hatfield J, Ohnuma T, Treggiari M, Colton K, Arulraja E, Vavilala M, Laskowitz D, Mathew J, Hernandez A, James M, Raghunathan K, Krishnamoorthy V. Early Beta-Blocker Utilization in Critically Ill Patients With Moderate-Severe Traumatic Brain Injury: A Retrospective Cohort Study. Journal Of Intensive Care Medicine 2024, 39: 875-882. PMID: 38449336, DOI: 10.1177/08850666241236724.Peer-Reviewed Original ResearchAssociated with hospital mortalityRetrospective cohort studyLength of stayModerate-severe TBITraumatic brain injuryCohort studyIntensive care unitBeta-blocker classHospital mortalityUtilization patternsClaims-based datasetHospital length of stayIll patientsCritically ill patientsIntensive care unit length of stayBrain injuryBeta-blockersHealthcare databasesInclusion criteriaSecondary outcomesPremier Healthcare DatabasePrimary outcomeVasopressor utilizationIntensive care unit stayHospitalEnhanced Recovery After Surgery Cardiac Society turnkey order set for prevention and management of postoperative atrial fibrillation after cardiac surgery: Proceedings from the American Association for Thoracic Surgery ERAS Conclave 2023
Chatterjee S, Cangut B, Rea A, Salenger R, Arora R, Grant M, Morton-Bailey V, Hirji S, Engelman D, Group E, Gregory A, Lobdell K, Hui D, Puskas J, Gaudino M, Crisafi C, Reddy V. Enhanced Recovery After Surgery Cardiac Society turnkey order set for prevention and management of postoperative atrial fibrillation after cardiac surgery: Proceedings from the American Association for Thoracic Surgery ERAS Conclave 2023. JTCVS Open 2024, 18: 118-122. PMID: 38690434, PMCID: PMC11056439, DOI: 10.1016/j.xjon.2024.02.008.Peer-Reviewed Original ResearchPostoperative atrial fibrillationManagement of postoperative atrial fibrillationCardiac surgeryAtrial fibrillationDevelopment of postoperative atrial fibrillationOccurrence of postoperative atrial fibrillationAssociated with increased adverse eventsAdministration of beta-blockersClass IChronic atrial fibrillationPatient-specific risk profilesInitiate appropriate treatmentIndividual risk stratificationExpert consensus documentMultidisciplinary care pathwayElectrolyte normalizationPosterior pericardiotomyRhythm controlAdoption of evidence-based practicesBeta-blockersSurgical interventionRisk stratificationAdverse eventsAnticoagulation managementConsensus manuscript
2023
Drugs for spontaneous coronary dissection: a few untrusted options
Ilic I, Radunovic A, Timcic S, Odanovic N, Radoicic D, Dukuljev N, Krljanac G, Otasevic P, Apostolovic S. Drugs for spontaneous coronary dissection: a few untrusted options. Frontiers In Cardiovascular Medicine 2023, 10: 1275725. PMID: 38028484, PMCID: PMC10667692, DOI: 10.3389/fcvm.2023.1275725.Peer-Reviewed Original ResearchSpontaneous coronary artery dissectionDual antiplatelet therapyAntiplatelet therapyBeta-blockersRare cause of acute coronary syndromeLack of randomized studiesLeft ventricular ejection fractionSymptoms of heart failureCause of acute coronary syndromeRecurrence of SCADAngiotensin-converting enzyme inhibitorsVentricular ejection fractionSpontaneous coronary dissectionAngiotensin receptor blockersAcute coronary syndromeCoronary artery dissectionDecreased coronary flowLoop diureticsEjection fractionClinical presentationMineralocorticoid antagonistsP2Y12 inhibitorsRare causeRandomized studyArtery dissection
2020
A Dedicated Guideline Directed Medical Therapy Clinic Improves Quality of Care and Outcomes In Patients with Heart Failure and Reduced Ejection Fraction
Tiu J, Balakumaran K, Barry M, Cipriani K, Kearney L, Oranefo J, Kim M, Tabtabai S. A Dedicated Guideline Directed Medical Therapy Clinic Improves Quality of Care and Outcomes In Patients with Heart Failure and Reduced Ejection Fraction. Journal Of Cardiac Failure 2020, 26: s133. DOI: 10.1016/j.cardfail.2020.09.386.Peer-Reviewed Original ResearchTarget doses of beta-blockersProportion of patientsDoses of beta-blockersTarget doseMinnesota Living with Heart Failure QuestionnaireHeart failure parametersEjection fractionHeart failurePHQ-9 scoresBeta-blockersLV end-diastolic diameterAssociated with significant morbidityNYHA class IIEnd-diastolic diameterReduced ejection fractionNon-ischemic cardiomyopathyRegimen of medicationCongestive heart failureMedian PHQ-9 scoreResults of landmark trialsHeart failure diagnosisEnrollment of patientsImproving clinical outcomesHeart Failure QuestionnaireMonths post-interventionHemodynamic events during carotid stenting are associated with significant periprocedural stroke and adverse events
Arhuidese I, Ottinger M, Shukla A, Moudgil N, Armstrong P, Illig K, Johnson B, Shames M. Hemodynamic events during carotid stenting are associated with significant periprocedural stroke and adverse events. Journal Of Vascular Surgery 2020, 71: 1941-1953.e1. PMID: 32085961, DOI: 10.1016/j.jvs.2019.05.056.Peer-Reviewed Original ResearchConceptsPeriprocedural strokePeriprocedural hypertensionHemodynamic eventsLength of stayCarotid symptomsPreprocedure medicationsMyocardial infarctionAngiotensin-converting enzyme inhibitorsCox regression analysisSymptomatic carotid diseaseVascular Quality InitiativePopulation-based cohortAssociated with significant increasesSusceptible patientsPeriprocedural outcomesBeta-blockersAdverse eventsKaplan-MeierComparing PatientsCAS proceduresPeriprocedural hypotensionCardiac diseaseCarotid angioplastyCarotid stentingCarotid disease
2019
Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC).
Patel V, Oh W, Galsky M, Liaw B, Tsao C. Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC). Journal Of Clinical Oncology 2019, 37: 467-467. DOI: 10.1200/jco.2019.37.7_suppl.467.Peer-Reviewed Original ResearchCheckpoint inhibitorsDuration of therapyNon-BB groupBeta-blockersOverall survivalBB groupCD8+ T cell activationEfficacy of checkpoint inhibitorsPD-1/PD-L1 blockadePre-clinical mouse modelImmune checkpoint inhibitorsPharmacological beta-blockadeCheckpoint inhibitor therapyPD-1/PD-L1IRB-approved databaseSingle-center cohortResponse of immunotherapyOutcomes of patientsMolecular targeted therapyRenal cell carcinomaKaplan-Meier curvesT cell activationCox proportional hazards modelsGU cancer patientsProportional hazards model
2015
Beta-blocker use is associated with lower stroke and death after carotid artery stenting
Obeid T, Arhuidese I, Gaidry A, Qazi U, Abularrage C, Goodney P, Cronenwett J, Malas M. Beta-blocker use is associated with lower stroke and death after carotid artery stenting. Journal Of Vascular Surgery 2015, 63: 363-369. PMID: 26526052, PMCID: PMC5292260, DOI: 10.1016/j.jvs.2015.08.108.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic beta-AntagonistsAdultAgedAged, 80 and overAngioplastyCarotid Artery DiseasesChi-Square DistributionDatabases, FactualFemaleHemodynamicsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioProtective FactorsRetrospective StudiesRisk AssessmentRisk FactorsStentsStrokeTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsCarotid artery stentingBeta-blocker usePostprocedural hypertensionPostprocedural hypotensionBeta-blockersArtery stentingAssociated with postprocedural hypotensionEffect of preoperative medicationOutcomes of carotid artery stentingPredictors of postoperative strokeAssociated with lower strokeSelection of patientsMultivariate logistic regression modelDistal embolic protection useVascular Quality InitiativeMyocardial infarction rateGranular clinical dataMultiple controlled trialsPreoperative medicationsPostoperative strokeBeta blockersPeriprocedural stroke/deathStroke/death rateLogistic regression modelsStroke/death risk
2012
Beta‐blockers in patients with refractory ascites: To treat or not to treat. That is the question? But, what is the answer?
Guevara M, Groszmann R, Iwakiri Y, Taddei T. Beta‐blockers in patients with refractory ascites: To treat or not to treat. That is the question? But, what is the answer? Hepatology 2012, 56: 384-386. PMID: 22454325, DOI: 10.1002/hep.25724.Peer-Reviewed Original ResearchParacentesis-induced circulatory dysfunctionIncidence of paracentesis-induced circulatory dysfunctionPlasma renin concentrationRefractory ascitesBeta-blockersArterial pressureDevelopment of paracentesis-induced circulatory dysfunctionHeart rateTreated with beta-blockersChild-Pugh C.Intravenous albumin administrationBeta-blocker therapyEradication of varicesCross-over studyBaseline 1 weekEndoscopic eradicationAlbumin administrationBeta blockersMELD scoreRenin concentrationCirculatory dysfunctionAscitesCirrhosisParacentesisPatients
2009
Early On–Cardiopulmonary Bypass Hypotension and Other Factors Associated With Vasoplegic Syndrome
Levin M, Lin H, Castillo J, Adams D, Reich D, Fischer G. Early On–Cardiopulmonary Bypass Hypotension and Other Factors Associated With Vasoplegic Syndrome. Circulation 2009, 120: 1664-1671. PMID: 19822810, DOI: 10.1161/circulationaha.108.814533.Peer-Reviewed Original ResearchConceptsCardiopulmonary bypassPoor clinical outcomesArterial blood pressure curveArterial pressureVasoplegic syndromeClinical outcomesAdult cardiac surgery casesBlood pressure curvePredictor of poor clinical outcomePost-CPB hematocritAngiotensin-converting enzyme inhibitorsCardiac surgery casesPost-CPB periodMean arterial pressurePredictors of patientsLength of bypassLength of stayClinically significant declineAdditive EuroSCOREPreoperative useVasodilatory shockBeta-blockersIntraoperative useSurgery casesProcedure type
2006
Quantitative Assessment of Left Ventricular Size and Function
Sugeng L, Mor-Avi V, Weinert L, Niel J, Ebner C, Steringer-Mascherbauer R, Schmidt F, Galuschky C, Schummers G, Lang R, Nesser H. Quantitative Assessment of Left Ventricular Size and Function. Circulation 2006, 114: 654-661. PMID: 16894035, DOI: 10.1161/circulationaha.106.626143.Peer-Reviewed Original ResearchConceptsCardiac CTEnd-systolic volumeLeft ventricular sizeCardiac MRRT3DE measurementsEjection fractionVentricular sizeEnd-diastolicAssessment of left ventricular sizeCardiac CT measuresReal-time 3D echocardiographyMeasurements of left ventricular sizeEnd-diastolic volumeMeasurement of left ventricular volumeLeft ventricular volumeBland-Altman analysisLimits of agreementStandard reference techniquePhilips 7500Intertechnique agreementRT3DE dataEndocardial definitionLive 3D imagingBeta-blockersVentricular volume
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply